Postpartum Hemorrhage

Table of Contents

  1. Overview and Definition
  2. The Four T's Framework
  3. Risk Factors and Prevention
  4. Recognizing PPH Early
  5. Medical Management
  6. Procedural and Surgical Interventions
  7. Massive Transfusion and Blood Products
  8. Placenta Accreta Spectrum
  9. Secondary Postpartum Hemorrhage
  10. When to Call Your Doctor Immediately
  11. Key Research Papers
  12. Featured Videos
  13. Connections

Overview and Definition

Postpartum hemorrhage (PPH) is defined as cumulative blood loss of 1,000 mL or more, or blood loss accompanied by signs and symptoms of hypovolemia (low blood volume), within 24 hours of delivery. This updated definition — adopted by the American College of Obstetricians and Gynecologists (ACOG) in 2017 — replaced the older thresholds of 500 mL after vaginal delivery and 1,000 mL after cesarean section, recognizing that any significant hemorrhage poses serious risk regardless of delivery route.

PPH is classified into two types based on timing:

The scale of this problem is staggering. PPH is the single most common cause of maternal mortality worldwide, responsible for approximately 25% of all maternal deaths globally. That translates to more than 70,000 women dying every year — the overwhelming majority of them in low- and middle-income countries where access to emergency obstetric care is limited.

In the United States, where maternal mortality has been rising rather than falling, PPH remains the most preventable cause of maternal death. Black women in the US face a 2 to 3 times higher risk of dying from obstetric hemorrhage than white women — a disparity driven by a combination of factors including underlying health conditions, disparities in care quality, and systemic barriers to timely recognition and treatment.

If you or someone you love is recovering from childbirth, it is completely natural to feel frightened by this topic. The most important thing to know is this: PPH is treatable when caught early. Hospitals with prepared hemorrhage response teams, quantitative blood loss monitoring, and clear escalation protocols have dramatically reduced maternal deaths from this cause. Knowing the warning signs — and acting on them quickly — is the most powerful tool you have.

Back to Table of Contents

The Four T's Framework

Clinicians use a simple framework called the "Four T's" to remember the causes of postpartum hemorrhage. Each category requires a different treatment approach, so identifying the correct cause quickly is critical.

Tone — Uterine Atony (70–80% of PPH)

Uterine atony is by far the most common cause of PPH. After the placenta delivers, the uterus must contract firmly to compress the blood vessels at the placental attachment site. When the uterus is soft and fails to contract — called "boggy" — bleeding continues unchecked from hundreds of open blood vessels.

Risk factors for uterine atony include:

Tissue — Retained Placenta or Membranes (approximately 10% of PPH)

If any portion of the placenta or fetal membranes remains inside the uterus after delivery, it prevents the uterus from contracting fully and keeps blood vessels open. The uterus cannot clamp down around placental tissue. Retained placenta becomes a more serious concern in placenta accreta spectrum disorders, where the placenta is abnormally attached to or invades the uterine wall (see the Placenta Accreta Spectrum section below).

Trauma — Lacerations, Rupture, and Hematoma

Physical trauma to the birth canal or uterus causes bleeding that continues even when the uterus itself is well-contracted. Sources include:

Thrombin — Coagulation Disorders (approximately 1% of PPH)

The blood's ability to clot can fail either because of a pre-existing clotting disorder or because of conditions that develop during pregnancy and delivery:

Coagulopathy can also develop as a consequence of massive PPH itself — when large volumes of blood are lost and replaced with fluids that lack clotting factors, the blood loses its ability to form clots, creating a vicious cycle.

Back to Table of Contents

Risk Factors and Prevention

Understanding which patients are at highest risk allows care teams to prepare in advance — having blood products available, assembling experienced personnel, and activating hemorrhage protocols before a crisis occurs.

High-Risk Factors

Moderate-Risk Factors

Active Management of the Third Stage of Labor (AMTSL)

The single most effective intervention for preventing PPH is called active management of the third stage of labor (AMTSL). This is the gold standard of care in hospitals worldwide and reduces PPH risk by approximately 60%. It consists of three components delivered immediately after the baby is born:

  1. Oxytocin 10 IU intramuscularly: Given immediately after delivery of the baby (before the placenta is out); causes the uterus to contract and dramatically reduces blood loss
  2. Controlled cord traction: Gentle downward traction on the umbilical cord, combined with upward counter-pressure on the lower uterus, to deliver the placenta efficiently
  3. Uterine massage: Sustained massage of the uterine fundus after the placenta delivers to encourage and maintain contraction

Tranexamic Acid (TXA) for Prevention and Treatment

Tranexamic acid is an antifibrinolytic drug that prevents blood clots from breaking down prematurely, allowing the body's natural clotting to work more effectively. The landmark WOMAN Trial (2017, published in The Lancet) enrolled 20,060 women with PPH across 21 countries and found that giving TXA 1 gram intravenously within 3 hours of birth reduced deaths from hemorrhage by 31% — with no increase in adverse events. The benefit was time-dependent: earlier administration was more effective.

Based on this evidence, the World Health Organization (WHO) and ACOG now recommend TXA 1g IV as a routine add-on treatment for PPH, given within 3 hours of delivery onset.

Back to Table of Contents

Recognizing PPH Early

One of the most dangerous aspects of postpartum hemorrhage is how easy it is to underestimate. Visual estimates of blood loss are notoriously inaccurate — studies show that clinicians consistently underestimate actual blood loss by 30 to 50%. This is made worse by the fact that pregnant women's blood volume increases by approximately 40% during pregnancy, which means a woman can lose 1,500 mL or more before her blood pressure drops significantly. By the time hypotension appears, the hemorrhage is already severe.

Signs of Active PPH

Signs of Hemorrhagic Shock (in order of appearance)

  1. Tachycardia (HR >100): The earliest and most reliable sign of significant blood loss. The body accelerates the heart rate to compensate for falling cardiac output before blood pressure drops.
  2. Anxiety and restlessness: Inadequate brain perfusion causes agitation before consciousness is lost
  3. Pallor and cool, clammy skin: Vasoconstriction diverts blood from the skin to vital organs
  4. Decreased urine output: The kidneys begin to shut down as perfusion pressure falls
  5. Hypotension: A late sign. Blood pressure may not fall significantly until 1,500 mL or more have been lost — at which point the situation is already life-threatening.
  6. Altered consciousness: Confusion, loss of consciousness

The Shock Index

The Shock Index (SI) is calculated by dividing the heart rate by the systolic blood pressure (HR ÷ SBP). It is a simple bedside tool that detects hemodynamic deterioration earlier than blood pressure alone:

Quantitative Blood Loss (QBL)

Modern obstetric units use quantitative blood loss measurement instead of visual estimation. This involves weighing blood-soaked materials (pads, drapes, sponges) before and after use, and measuring blood in graduated collection devices. QBL is significantly more accurate than visual estimation and allows earlier recognition of dangerous blood loss before the patient becomes clinically unstable.

Back to Table of Contents

Medical Management

When PPH is identified, treatment follows a stepwise uterotonic ladder — using medications in sequence to stimulate uterine contraction and reduce bleeding. Multiple agents are frequently used in combination when single-drug therapy is insufficient.

First-Line: Oxytocin

Oxytocin (Pitocin) remains the first-line uterotonic for PPH. It is given as 10–40 IU added to 1 liter of normal saline infused intravenously. Oxytocin acts within minutes to stimulate uterine smooth muscle contraction. An important caution: rapid IV bolus (push) administration can cause profound hypotension and even cardiac arrest — always administer as a diluted infusion, not a rapid push.

Second-Line: Methylergonovine (Methergine)

Methylergonovine 0.2 mg given intramuscularly causes sustained uterine contraction through ergot alkaloid action. It is highly effective but carries a critical contraindication: it must not be given to women with hypertension or preeclampsia because it causes severe vasoconstriction that can precipitate hypertensive crisis, stroke, or myocardial infarction.

Carboprost (15-Methyl Prostaglandin F2α / Hemabate)

Carboprost 0.25 mg given intramuscularly can be repeated every 15 to 90 minutes, up to a maximum of 8 doses. It is a potent uterotonic prostaglandin but carries a critical contraindication: it must not be given to women with asthma because it causes bronchospasm and can trigger a severe asthma attack.

Misoprostol

Misoprostol (600–1000 mcg given rectally or sublingually) is a prostaglandin E1 analogue that has become particularly valuable in resource-limited settings because it is inexpensive, does not require refrigeration, and can be administered without IV access. Its efficacy is somewhat lower than parenteral uterotonics, and it commonly causes fever, chills, and shivering as side effects. WHO includes it on the Essential Medicines List specifically because of its accessibility in low-resource environments.

Tranexamic Acid (TXA)

Tranexamic acid 1 gram IV given over 10 minutes is added to uterotonic therapy when hemorrhage is ongoing. Based on the WOMAN Trial (2017), it significantly reduces mortality from PPH when given within 3 hours of delivery. A second 1g dose can be given 30 minutes later if bleeding continues. TXA is not a uterotonic — it works by stabilizing clots rather than contracting the uterus — and is always used in addition to, not instead of, uterotonic drugs.

Combination Therapy

When oxytocin alone is insufficient, a second or third uterotonic is added rather than waiting to see if the first agent eventually works. Speed of escalation matters: every minute of ongoing hemorrhage increases the risk of coagulopathy, shock, and organ damage.

Back to Table of Contents

Procedural and Surgical Interventions

When medications are insufficient to control hemorrhage, procedural and surgical escalation follows a logical sequence — attempting to preserve the uterus where possible before moving to definitive surgical control.

Intrauterine Balloon Tamponade

The Bakri balloon is inserted into the uterine cavity and inflated with 300–500 mL of saline. The pressure physically compresses the open blood vessels on the uterine interior. A key concept is the "tamponade test": if bleeding stops or dramatically slows after balloon inflation, it confirms that tamponade alone is sufficient to achieve hemostasis, and surgical intervention can be avoided. The balloon is left in place for 12–24 hours, then gradually deflated. It buys time, stabilizes the patient, and allows transfer if needed.

Uterine Compression Sutures

The B-Lynch suture and similar brace sutures physically compress the anterior and posterior uterine walls together, mimicking the squeezing action of uterine contraction. These can be combined with tamponade balloon use. They are fertility-preserving and effective for diffuse uterine atony when medications have failed.

Uterine Artery Ligation

Bilateral surgical ligation (tying off) of the uterine arteries reduces uterine blood flow by approximately 80%, dramatically reducing hemorrhage from the uterine body. This fertility-preserving approach is used when simpler measures have failed and the source is identified as uterine.

Internal Iliac Artery Ligation

Ligation of the internal iliac (hypogastric) arteries reduces pulse pressure to the uterine vasculature, allowing clot formation. However, this procedure carries a 40% failure rate, requires significant surgical expertise, and risks injury to adjacent structures. It has largely been supplanted by interventional radiology approaches at centers with IR availability.

Uterine Artery Embolization (UAE)

Interventional radiology-guided UAE involves threading a catheter through the femoral artery to the uterine arteries and injecting particles that block blood flow to the bleeding vessels. It is highly effective, fertility-preserving, and avoids major surgery — but requires a hemodynamically stable patient who can tolerate the IR suite and time for the procedure. It is ideal for women who have stopped active hemorrhage but remain at high risk for recurrent bleeding, particularly in placenta accreta spectrum.

Peripartum Hysterectomy

Peripartum hysterectomy — surgical removal of the uterus during or immediately after delivery — is the definitive treatment for uncontrollable PPH. It is a last resort but is immediately effective: hemorrhage stops as soon as the uterus is removed. Peripartum hysterectomy occurs in approximately 1 in 1,000 deliveries in the US. Blood transfusion is almost always required. While it ends future fertility, it saves the mother's life when other measures have failed or are unavailable. Timely decision-making is critical — delayed hysterectomy in the setting of ongoing massive hemorrhage and developing coagulopathy significantly increases mortality risk.

Back to Table of Contents

Massive Transfusion and Blood Products

Major PPH rapidly depletes the blood of both oxygen-carrying red cells and the clotting factors needed to stop bleeding. Replacing only red blood cells without simultaneously replacing clotting factors leads to dilutional coagulopathy — the blood's clotting machinery is washed out by transfused crystalloid and packed cells, and a vicious cycle begins where bleeding prevents clotting, and inability to clot perpetuates bleeding.

Massive Transfusion Protocol (MTP)

The MTP is a hospital-wide activation that coordinates rapid delivery of blood products in fixed ratios. In obstetric hemorrhage, the target ratio is approximately 1:1:1 (one unit each of packed red blood cells, fresh frozen plasma, and platelets). This balanced replacement approach has been shown to reduce mortality compared to RBC-predominant strategies. The key is to activate the MTP early — before coagulopathy develops — rather than waiting until it is already established.

Packed Red Blood Cells (pRBC)

Transfused to restore oxygen-carrying capacity. General triggers: hemoglobin below 7 g/dL in a stable patient, or any level in a patient with ongoing active bleeding and hemodynamic instability. In the setting of massive PPH, transfusion is driven by clinical status and blood loss, not laboratory values alone.

Fresh Frozen Plasma (FFP)

FFP contains all clotting factors and is given to correct coagulopathy. Trigger: INR greater than 1.5, or after every 4–6 units of pRBC as part of the MTP ratio.

Cryoprecipitate

Cryoprecipitate is rich in fibrinogen, factor VIII, and von Willebrand factor. It is critically important in PPH because fibrinogen drops precipitously with massive hemorrhage and is the earliest coagulation parameter to become critically low. Target: fibrinogen greater than 200 mg/dL. DIC from amniotic fluid embolism or HELLP syndrome particularly depletes fibrinogen and requires aggressive cryoprecipitate replacement.

Platelets

Platelets are transfused when the count falls below 50,000/μL in a patient with active bleeding, or below 100,000/μL when surgical intervention is planned.

Cell Salvage

Intraoperative cell salvage — collecting, washing, and re-infusing the patient's own shed blood — is acceptable and increasingly used in obstetric hemorrhage, particularly in placenta accreta cases and women who decline allogenic blood transfusion for religious reasons. A leukocyte depletion filter is recommended when re-infusing salvaged blood in obstetrics.

Goal-Directed Therapy

Point-of-care viscoelastic testing (TEG — thromboelastography; ROTEM — rotational thromboelastometry) provides real-time information about the specific component of the clotting cascade that is failing, allowing targeted replacement rather than empiric ratio-based transfusion. This approach reduces total blood product use while maintaining hemostasis. The clinical principle is: "Transfuse to prevent DIC, not to treat it." By the time DIC is fully established, the treatment needed becomes exponentially more complex.

Back to Table of Contents

Placenta Accreta Spectrum

Placenta accreta spectrum (PAS) represents one of the most serious and rapidly increasing complications in modern obstetrics. It occurs when the placenta abnormally adheres to or invades the uterine wall, making it impossible to deliver the placenta normally without catastrophic hemorrhage.

The Spectrum of Severity

A Rapidly Rising Problem

The incidence of placenta accreta spectrum has increased dramatically in parallel with the rising cesarean section rate. In the 1960s, PAS occurred in approximately 1 in 30,000 deliveries. By 2016, it occurred in 1 in 533 deliveries — a nearly 60-fold increase. This directly reflects the cesarean delivery rate, because uterine scars from prior cesareans are the primary risk factor for PAS.

Risk Factors

The most powerful risk factor combination is placenta previa (placenta covering the cervix) in a woman with prior cesarean section. The risk increases dramatically with each additional scar:

Diagnosis

Prenatal ultrasound is the primary diagnostic tool. Suspicious findings include: loss of the normal retroplacental clear space (the dark band between placenta and myometrium), multiple irregular vascular lacunae (the "swiss cheese" appearance of the placenta on ultrasound), and irregularity or loss of the bladder wall in percreta. MRI provides additional detail, particularly for assessing lateral spread and bladder involvement, but is used as an adjunct to, not replacement for, ultrasound. There is no reliable blood test for PAS.

Management

Confirmed or suspected PAS should be managed at a center with expertise and multidisciplinary resources, including an experienced obstetric surgeon, urology (for bladder involvement), interventional radiology, and a blood bank prepared for massive transfusion. Delivery is typically planned at 34–36 weeks of gestation (before labor begins spontaneously). The planned management is usually hysterectomy with the placenta left in situ — the single most dangerous maneuver in PAS is attempting to manually remove the placenta, which can trigger uncontrollable hemorrhage within seconds. In carefully selected cases at expert centers, conservative (uterus-sparing) management with methotrexate and expectant monitoring has been attempted experimentally.

Back to Table of Contents

Secondary Postpartum Hemorrhage

Secondary PPH is heavy vaginal bleeding that occurs between 24 hours and 12 weeks after delivery, after an initial period of normal or expected postpartum bleeding. It is far less common than primary PPH but can be just as alarming and — if ignored — potentially dangerous.

Timing and Causes

Secondary PPH most commonly occurs between days 8 and 14 postpartum — roughly the second week after delivery. The most common causes are:

Diagnosis

Pelvic ultrasound is the primary diagnostic tool. Heterogeneous (irregular, mixed-signal) contents within the uterine cavity suggest retained placental tissue. A hypervascular lesion on color Doppler raises concern for AVM. Uterine dimensions on ultrasound help assess involution progress.

Treatment

Normal Postpartum Bleeding (Lochia) vs. Abnormal Bleeding

Understanding what is expected helps mothers recognize when something is wrong:

Red flags for abnormal secondary bleeding: bleeding that was tapering and then suddenly restarts or becomes heavier; soaking more than one pad per hour; passage of large clots; fever with increased bleeding; foul odor. These warrant same-day contact with your provider or emergency evaluation.

Back to Table of Contents

When to Call Your Doctor Immediately

Whether you delivered vaginally or by cesarean section, in the hospital or at a birthing center, knowing the warning signs of postpartum hemorrhage could save your life. Many maternal deaths from PPH in high-income countries occur after discharge from the hospital, when women experience heavy bleeding at home and delay seeking care.

Call 911 or Go to the Emergency Room Immediately

Call Your OB or Midwife the Same Day

A Note About Blood Loss and Pregnancy

During pregnancy, your blood volume increases by about 40%. This is a protective adaptation — but it also means you can lose a significant amount of blood before you feel dramatically unwell. Do not wait until you feel terrible to call for help. If something feels wrong, trust your instincts and make the call. Healthcare providers would far rather evaluate a concern that turns out to be normal bleeding than have a patient delay care during a true emergency.

Racial Disparities in PPH Outcomes — What You Can Do

Black women in the United States are 2 to 3 times more likely to die from obstetric hemorrhage than white women. This disparity is not explained by biology — it reflects differences in access to high-quality care, systemic barriers to being heard and taken seriously by healthcare providers, and higher rates of underlying conditions that increase PPH risk. If you are Black and feel that your concerns are not being taken seriously during or after delivery, you have the right to ask to speak with a charge nurse, attending physician, or patient advocate. Bring a supportive partner or family member who can advocate for you. Know the warning signs. Ask your care team directly: "What is my postpartum hemorrhage risk, and what is your plan if I start bleeding heavily?"

Back to Table of Contents

Key Research Papers

  1. Sheldon WR et al. — Postpartum Hemorrhage Management, Risks, and Maternal Outcomes: Findings from the WHO Multicountry Survey on Maternal and Newborn Health (2014)
    Large multicountry WHO survey examining the epidemiology, management practices, and maternal outcomes of postpartum hemorrhage across 29 countries. Provides foundational data on global PPH burden and care gaps.
    PMID 25238107
  2. Sentilhes L et al. — Tranexamic Acid for the Prevention and Treatment of Postpartum Hemorrhage (2018)
    Comprehensive review synthesizing evidence for TXA use in PPH prevention and treatment, including a discussion of the WOMAN Trial results and their implications for clinical practice.
    PMID 29753714
  3. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage (2012)
    The foundational World Health Organization clinical guidelines establishing global standards of care for PPH prevention (AMTSL, uterotonics) and treatment, forming the basis for care in both high-income and resource-limited settings.
    PMID 23586136
  4. WOMAN Trial Collaborators — Effect of Early Tranexamic Acid Administration on Mortality, Hysterectomy, and Other Morbidities in Women with Post-Partum Haemorrhage (Lancet, 2017)
    The landmark randomized controlled trial of tranexamic acid in PPH. Enrolled 20,060 women across 21 countries; demonstrated 31% reduction in death from hemorrhage when TXA was given within 3 hours of birth. This single trial changed global PPH management guidelines.
    PMID 28456509
  5. Creanga AA et al. — Maternal Mortality and Morbidity in the United States: Where Are We Now? (2014)
    Analysis of US maternal mortality trends identifying hemorrhage as a leading cause of preventable maternal death, with documentation of significant racial and ethnic disparities in outcomes.
    PMID 25114396
  6. Silver RM et al. — Maternal Morbidity Associated with Multiple Repeat Cesarean Deliveries (2006)
    Prospective cohort study demonstrating the dramatic increase in placenta accreta spectrum, hysterectomy, and PPH risk with increasing numbers of prior cesarean sections. Defined the data underlying the current risk tables for PAS by scar number.
    PMID 16946220
  7. Dyer RA et al. — Magnesium Sulphate as an Adjunct in the Management of Severe Hypertension and Postpartum Haemorrhage (2009)
    Clinical study examining the interaction between magnesium sulfate use and uterine atony risk, with implications for uterotonic dosing strategies in preeclamptic patients at risk for PPH.
    PMID 19461559
  8. Leduc D et al. — Active Management of the Third Stage of Labour (2009)
    SOGC clinical practice guideline establishing the evidence base and technical protocol for active management of the third stage of labor, the gold-standard preventive intervention for PPH.
    PMID 19765322
  9. Grotegut CA et al. — Oxytocin Exposure During Labor Among Women With Postpartum Hemorrhage Secondary to Uterine Atony (2011)
    Study examining the relationship between intrapartum oxytocin use and risk of subsequent uterine atony-related PPH, contributing to understanding of oxytocin receptor downregulation as a risk mechanism.
    PMID 21636079
  10. Fitzpatrick KE et al. — Incidence and Risk Factors for Placenta Accreta/Increta/Percreta in the UK: A National Case-Control Study (2012)
    Large national case-control study from the UK Obstetric Surveillance System defining the incidence, risk factors, and clinical management of placenta accreta spectrum, with data on outcomes by PAS subtype.
    PMID 22926048
  11. Bateman BT et al. — The Epidemiology of Postpartum Hemorrhage in a Large, Nationwide Sample of Deliveries (2010)
    Nationwide US epidemiological study using hospital discharge data to characterize PPH incidence, trends, risk factors, and associated outcomes, documenting rising rates over time.
    PMID 20220139
  12. Oyelese Y, Ananth CV — Postpartum Hemorrhage: Epidemiology, Risk Factors, and Causes (2010)
    Comprehensive epidemiological review organizing PPH causes within the Four T's framework, providing data on the relative prevalence of each etiologic category and their associated risk factors.
    PMID 20928274

Back to Table of Contents

Connections